MGMT and colorectal cancer: Researchers included colorectal cancer patients with O6-methylguanine-DNA-methyltransferase (MGMT)-deficient tumors that were also MMR-proficient and RAS-mutant in the Arethusa trial, a proof of concept trial that involved priming therapy with TMZ.